Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sage Therapeutic Com
(NQ:
SAGE
)
8.430
+0.340 (+4.20%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sage Therapeutic Com
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Sage Therapeutics to Present at the Stifel 2023 CNS Days
March 22, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics Appoints Jessica Federer to Board of Directors
March 16, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Analyst Creates Bullish Pitch For Sage Therapeutics Around Greater Enthusiasm For Its Depression Drug, Zuranolone
March 13, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 13, 2023
March 13, 2023
Via
Benzinga
What 5 Analyst Ratings Have To Say About Sage Therapeutics
March 09, 2023
Via
Benzinga
Earnings Scheduled For February 16, 2023
February 16, 2023
Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year...
Via
Benzinga
Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 13, 2023
Gainers Provention Bio, Inc. (NASDAQ: PRVB) shares jumped 250.8% to $23.50 after Sanofi announced it will acquire the company for $25 per share in cash.
Via
Benzinga
Illumina, Seagen And Other Big Stocks Moving Higher On Monday
March 13, 2023
U.S. stocks traded slightly lower, with the Nasdaq Composite dropping around 0.2% on Monday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Expert Ratings for Sage Therapeutics
December 06, 2022
Via
Benzinga
Sage Therapeutics's Return On Capital Employed Insights
December 05, 2022
Via
Benzinga
Sage Therapeutics/Biogen Highlight Additional Data From Depression Candidate
October 17, 2022
Via
Benzinga
Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone
March 08, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
February 28, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics Announces European Medicines Agency Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease
February 22, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Highlights Pipeline and Business Progress
February 16, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics-Biogen Partnered Depression Candidate Under Priority FDA Review, Analyst Says Its 'Incrementally Positive'
February 06, 2023
Via
Benzinga
Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
February 06, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
February 06, 2023
From
Biogen Inc.
Via
GlobeNewswire
Sage Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
February 02, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Provide Update on 2023 Key Initiatives at 41st Annual J.P. Morgan Healthcare Conference
January 08, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023
January 03, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
December 06, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
November 23, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics and Biogen to Host Investor Webcast on December 6, 2022 to Discuss Potential Commercialization Plans for Zuranolone
November 22, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates
November 14, 2022
EQNX::TICKER_START (NASDAQ:SAGE),NASDAQ:NERV),(NASDAQ:ATAI),(NYSE:CYBN),(TSXV:MRVL),(NEO:CYBN), EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Retirement
Exposures
Pension
Product Safety
Sage Therapeutics to Present at the Stifel 2022 Healthcare Conference
November 09, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
November 08, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics Appoints Laura M. Gault, M.D., Ph.D. as Chief Medical Officer
November 01, 2022
From
Sage Therapeutics
Via
Business Wire
Sage Therapeutics to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
October 25, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
November 01, 2022
Upgrades
Via
Benzinga
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.